Extent and Resistance Patterns of ESKAPE Pathogens Isolated in Pus Swabs from Hospitalized Patients

Masoud, Salim; Kovacevich, Anna; Gangji, Raidah; Nyawale, Helmut; Nyange, Mary; Ntukula, Albert

doi:10.1155/2022/3511306

Cited by 13 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Rising AMR has been a cause of urgent concern in recent times, with WHO rating it as one of the most significant public health threats [ 25 ]. Among the pathogens with the highest resistance rates, the ‘ESKAPE pathogens’ have the highest impact on outcomes [ 25 ]. AB is one of the ESKAPE pathogens with demonstrable resistance to all the commonly used antibiotics, including carbapenems [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

“…Among the pathogens with the highest resistance rates, the ‘ESKAPE pathogens’ have the highest impact on outcomes [ 25 ]. AB is one of the ESKAPE pathogens with demonstrable resistance to all the commonly used antibiotics, including carbapenems [ 25 ]. Although complete susceptibility reports were not available in most studies included in the review, overall, the resistance rates were high.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam (CS) is commonly used to treat AB, but the associated data are scarce. Methods: We conducted a systematic review of articles downloaded from Cochrane, Embase, PubMed, Scopus, and Web of Science (through June 2022) to study the efficacy of CS in treating AB infections. Our review evaluated patients treated with CS alone and CS in combination with other antibiotics separately. The following outcomes were studied: clinical cure, microbiological cure, and mortality from any cause. Results: We included 16 studies where CS was used for the treatment of AB infections. This included 11 studies where CS was used alone and 10 studies where CS was used in combination. The outcomes were similar in both groups. We found that the pooled clinical cure, microbiological cure, and mortality with CS alone for AB were 70%, 44%, and 20%, respectively. The pooled clinical cure, microbiological cure, and mortality when CS was used in combination with other antibiotics were 72%, 43%, and 21%, respectively. Conclusions: CS alone or in combination needs to be further explored for the treatment of AB infections. There is a need for randomized controlled trials with comparator drugs to evaluate the drug’s effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Wound infections afflict over 300 million individuals worldwide, and it is anticipated that treating these infections will cost at least $25 billion just in the United States of America . Necrotic tissue helps in the adhesion of bacteria in these infections while also providing nutrients that delay the healing of wounds by preventing re-epithelialization and extending inflammation.…”

Section: Biofilm Infection Controlmentioning

confidence: 99%

“…Wound infections afflict over 300 million individuals worldwide, and it is anticipated that treating these infections will cost at least $25 billion just in the United States of America. 153 Necrotic tissue helps in the adhesion of bacteria in these infections while also providing nutrients that delay the healing of wounds by preventing re-epithelialization and extending inflammation. The treatment of wound infections utilizes AgNPs that have been integrated into hydrogels or wound dressings.…”

Section: Biofilm Infection Controlmentioning

confidence: 99%

Perspectives on Usage of Functional Nanomaterials in Antimicrobial Therapy for Antibiotic-Resistant Bacterial Infections

et al. 2023

View full text Add to dashboard Cite

The clinical applications of nanotechnology are emerging as widely popular, particularly as a potential treatment approach for infectious diseases. Diseases associated with multiple drug-resistant organisms (MDROs) are a global concern of morbidity and mortality. The prevalence of infections caused by antibiotic-resistant bacterial strains has increased the urgency associated with researching and developing novel bactericidal medicines or unorthodox methods capable of combating antimicrobial resistance. Nanomaterial-based treatments are promising for treating severe bacterial infections because they bypass antibiotic resistance mechanisms. Nanomaterial-based approaches, especially those that do not rely on small-molecule antimicrobials, display potential since they can bypass drug-resistant bacteria systems. Nanoparticles (NPs) are small enough to pass through the cell membranes of pathogenic bacteria and interfere with essential molecular pathways. They can also target biofilms and eliminate infections that have proven difficult to treat. In this review, we described the antibacterial mechanisms of NPs against bacteria and the parameters involved in targeting established antibiotic resistance and biofilms. Finally, yet importantly, we talked about NPs and the various ways they can be utilized, including as delivery methods, intrinsic antimicrobials, or a mixture.

show abstract

Determination of potential combination of non‐β‐lactam, β‐lactam, and β‐lactamase inhibitors/β‐lactam enhancer against class D oxacillinases producing Acinetobacter baumannii: Evidence from in‐vitro, molecular docking and dynamics simulation

Gopikrishnan,

Ramireddy,

Varghese

et al. 2023

J of Cellular Biochemistry

View full text Add to dashboard Cite

Carbapenem-resistant Acinetobacter baumannii, a predominant nosocomial pathogen in hospitals of intensive care units, is associated with bacteremia and ventilator-associated pneumonia with a high-risk mortality rate. To increase the effectiveness of the β-lactam (BL) antibiotics, the use of β-lactamase inhibitors (BLI) acts as a booster when given in combination with BL antibiotics. To this aspect, we selected BL antibiotics of cefiderocol, cefepime, non-BL antibiotic eravacycline, BLI of durlobactam, avibactam, and a β-lactam enhancer (BLE) of zidebactam. To prove our hypothesis, we determined the minimum inhibitory concentration (MIC) of various BL or non-BL/BLI or BLE combinations using broth microdilution method followed by in silico analysis of molecular docking, molecular dynamics (MD) simulation, and molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) identifies the potential combination. In MIC testing, eravacycline, cefepime/zidebactam, cefiderocol/zidebactam, and eravacycline in combination with zidebactam or durlobactam were found to be effective against oxacillinases (OXAs) (OXA-23/

show abstract

Extent and Resistance Patterns of ESKAPE Pathogens Isolated in Pus Swabs from Hospitalized Patients

Cited by 13 publications

References 29 publications

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

Perspectives on Usage of Functional Nanomaterials in Antimicrobial Therapy for Antibiotic-Resistant Bacterial Infections

Determination of potential combination of non‐β‐lactam, β‐lactam, and β‐lactamase inhibitors/β‐lactam enhancer against class D oxacillinases producing Acinetobacter baumannii: Evidence from in‐vitro, molecular docking and dynamics simulation

Contact Info

Product

Resources

About